Browse Studies — Arctuva

Phase 3

A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.

A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal …

Subcutaneous Fat

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Caliway Biopharmaceuticals Co., Ltd.NCT07526974

Phase 3

A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.

A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal …

Subcutaneous Fat

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Caliway Biopharmaceuticals Co., Ltd.NCT07140939

Phase 3

A Phase 3b, Multicenter, Two Stage, Double-blind, Long Term Follow up and Open Label Extension Study of Participants Who Have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)

A Phase 3b, Multicenter, Two stage, Double-blind, Long term Follow up and Open-label Extension Study of Participants Who have Completed the CBL-0301 or CBL-030…

Subcutaneous Fat

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Caliway Biopharmaceuticals Co., Ltd.NCT07733947